EMA Recommends Granting a Marketing Authorisation for Tislelizumab
It is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy
FDA also approved LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic
Findings from the CARES-310 study
Findings from the phase III PRIME study
Findings from the machine learning modelling study
Findings from a randomised phase II study
It is indicated for the treatment of postmenopausal women and men with locally advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation
Findings from the AcSé Pembrolizumab study
Findings from the KEYNOTE-B61 study
Findings from a biomarker-driven phase II study
Findings from the IPSOS study
New indication concerns the treatment of metastatic NSCLC in combination with durvalumab and platinum-based chemotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.